Q-omics provides the consensus-scored UQCRFS1 profile across patient tissues and cancer cell-line models. UQCRFS1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, UQCRFS1 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, UQCRFS1 protein abundance shows 26,238 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight COAD, KIRC, and GBM as cancer lineages where UQCRFS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UQCRFS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UQCRFS1 survival associations across molecular data types. UQCRFS1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UQCRFS1 RNA expression–survival associations across cancer types. High UQCRFS1 expression shows unfavorable associations in UVM, HNSC and UCEC, but favorable associations in COAD, KIRC and KIRP. The COAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for UQCRFS1 RNA expression.
This table summarizes UQCRFS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for UQCRFS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UQCRFS1 shows lower tumor expression in KIRC, COAD, KIRP, THCA and HNSC and higher tumor expression in LIHC. The KIRC box plot shows higher UQCRFS1 RNA expression in normal versus tumor tissue (log2 FC = −1.296, t-test p < 0.001).
This table shows molecular features associated with UQCRFS1 in patient tissues and cancer cell lines. In patient samples, UQCRFS1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, UQCRFS1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LIVER and UPPER_AERODIGESTIVE_TRACT.
